KPV: Mechanism, Handling & Research Guide
Also known as: KPV, Lys-Pro-Val, KPV tripeptide, alpha-MSH(11-13), alpha-MSH C-terminal tripeptide
What is KPV?
KPV (Lysine-Proline-Valine) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically positions 11-13. Despite being only three amino acids, KPV retains the potent anti-inflammatory activity of the full-length hormone while lacking melanotropic and steroidogenic effects. KPV suppresses inflammation by inhibiting NF-kB nuclear translocation and reducing pro-inflammatory cytokine production, including IL-1beta, IL-6, and TNF-alpha. It enters cells and interacts directly with inflammatory signaling cascades independently of melanocortin receptors. Research published in the Journal of Biological Chemistry by Brzoska et al. demonstrated that KPV inhibited NF-kB activation in human intestinal epithelial cells, reducing inflammatory gene expression by 60-80% at micromolar concentrations. Studies in murine colitis models published in Inflammatory Bowel Diseases showed that oral and intracolonic KPV use significantly reduced disease activity index scores, colonic inflammation, and histological damage. Dalmasso et al. (2008) in PLoS ONE confirmed that KPV-loaded nanoparticles effectively targeted inflamed colonic tissue and accelerated mucosal healing. Compared to full-length alpha-MSH, KPV offers the advantage of anti-inflammatory activity without pigmentation effects or hormonal side effects. Unlike conventional anti-inflammatory agents such as corticosteroids or NSAIDs, KPV targets intracellular NF-kB signaling rather than cyclooxygenase or glucocorticoid receptor pathways, representing a mechanistically distinct approach to inflammation modulation. Store lyophilized KPV at -20°C. Reconstitute with bacteriostatic water and refrigerate at 2-8°C, using within 4 weeks. KPV is researched by gastroenterologists studying inflammatory bowel disease, dermatologists investigating anti-inflammatory skin treatments, and immunologists examining NF-kB-dependent inflammatory pathways.
KPV Research Applications
In published and preclinical research, KPV has been studied across the following areas:
- Intestinal inflammation and IBD models
- Anti-inflammatory pathway modulation
- ECM-remodeling and fibrosis research
- Antimicrobial activity studies
KPV in Research: Study Context
Published preclinical literature characterizes KPV as the C-terminal tripeptide (positions 11-13) of alpha-MSH that retains anti-inflammatory activity while lacking the melanotropic effects of the parent hormone. In vitro and rodent colitis studies report that KPV is taken up by the di/tripeptide transporter PepT1 in intestinal epithelial and immune cells and attenuates NF-kB and MAP-kinase signaling and pro-inflammatory cytokine output (Dalmasso et al., Gastroenterology 2008), and separate work documents antimicrobial activity of alpha-MSH C-terminal peptides against S. aureus and C. albicans (Cutuli et al., J Leukoc Biol 2000). For laboratory research use only; KPV is not FDA-approved and no human concentration is established. Reconstitute the lyophilized powder with bacteriostatic water to a defined working concentration (e.g., 10 mg/mL for a 10 mg vial) for in-vitro and benchtop assay use, reference the primary literature, and document the lot-specific Certificate of Analysis (COA).
How KPV Compares
Researchers frequently evaluate KPV alongside related compounds:
- KPV vs LL-37 — LL-37 is a 37-residue cationic peptide that directly disrupts microbial membranes, whereas KPV is a tripeptide studied mainly for NF-kB-targeted anti-inflammatory signaling; both appear in innate-immunity research but via distinct mechanisms.
- KPV vs BPC-157 — BPC-157 is studied for broad regenerative/angiogenic signaling (NO pathway, growth factors), while KPV is a narrower NF-kB-focused anti-inflammatory tripeptide; researchers contrast specific versus broad mechanism in tissue-inflammation models.